| Literature DB >> 31734366 |
Rezvan Yazdian-Robati1, Payam Bayat2, Fatemeh Oroojalian3, Mehryar Zargari1, Mohammad Ramezani4, Seyed Mohammad Taghdisi5, Khalil Abnous6.
Abstract
Nucleolin or C23, is one of the most abundant non-ribosomal phosphoproteins of nucleolus. However, in several cancers, nucleolin is highly expressed both intracellularly and on the cell surface. So, it is considered as a potential target for the diagnosis and cancer therapy. Targeting nucleolin by compounds such as AS1411 aptamer can reduce tumor cell growth. In this regard, interest has increased in nucleolin as a molecular target for overcoming cancer therapy challenges. This review paper addressed recent progresses in nucleolin targeting by the G-rich AS1411 aptamer in the field of cancer therapy mainly over the past three years.Entities:
Keywords: AS1411 aptamer; Nucleolin; Targeted therapy
Mesh:
Substances:
Year: 2019 PMID: 31734366 DOI: 10.1016/j.ijbiomac.2019.11.118
Source DB: PubMed Journal: Int J Biol Macromol ISSN: 0141-8130 Impact factor: 6.953